Israel - English - Ministry of Health

kamada ltd, israel - human hepatitis b immunoglobulin - solution for infusion - human hepatitis b immunoglobulin 50 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - prophylaxis against hepatitis b in adults and children over 2 years of age who have not been vaccinated against hepatitis b (including persons whose vaccination is incomplete or missing) who are at risk of infection with hepatitis b by accidental contact with hepatitis b virus containing material following: - percutaneous exposure (e.g. accidental needle stick). - direct mucous membrane contact. when the administration of an intramuscular hepatitis b immunoglobulin is not possible. the immunoglobulin should be administered in association with hepatitis b vaccine. prophylaxis against re-infection of a transplanted liver in patients who carry the surface antigen of the hepatitis b virus. immunoprophylaxis of hepatitis b in the newborn of a hepatitis b virus carrier mother.

Australia - English - Department of Health (Therapeutic Goods Administration)

missing in action pty ltd - fish oil - rich in omega-3 acids -

Australia - English - Department of Health (Therapeutic Goods Administration)

missing in action pty ltd - fish oil - rich in omega-3 acids -

Australia - English - Department of Health (Therapeutic Goods Administration)

missing in action pty ltd - ubidecarenone -

Australia - English - Department of Health (Therapeutic Goods Administration)

missing in action pty ltd - dl-alpha tocopheryl acetate -

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 250 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 500 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 1000 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

European Union - English - EMA (European Medicines Agency)

retrophin europe ltd - cholic acid - metabolism, inborn errors - bile and liver therapy - cholic acid fgk is indicated for the treatment of inborn errors of primary bile acid synthesis, in infants from one month of age for continuous lifelong treatment through adulthood, encompassing the following single enzyme defects:sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, ctx) deficiency;2- (or alpha-) methylacyl-coa racemase (amacr) deficiency;cholesterol 7 alpha-hydroxylase (cyp7a1) deficiency.

European Union - English - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - velaglucerase alfa - gaucher disease - other alimentary tract and metabolism products, - vpriv is indicated for long-term enzyme-replacement therapy (ert) in patients with type-1 gaucher disease.